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Abstract
Objectives
The aim of this multicenter retrospective study was to investigate safety and efficacy of
direct acting antiviral (DAA) treatment in the rare subgroup of patients with HCV/HIV-coin-
fection and advanced liver cirrhosis on the liver transplant waiting list or after liver transplan-
tation, respectively.
Methods
When contacting 54 German liver centers (including all 23 German liver transplant centers),
12 HCV/HIV-coinfected patients on antiretroviral combination therapy were reported having
received additional DAA therapy while being on the waiting list for liver transplantation
(patient characteristics: Child-Pugh A (n = 6), B (n = 5), C (n = 1); MELD range 7–21; HCC
(n = 2); HCV genotype 1a (n = 8), 1b (n = 2), 4 (n = 2)). Furthermore, 2 HCV/HIV-coinfected
patients were denoted having received DAA therapy after liver transplantation (characteris-
tics: HCV genotype 1a (n = 1), 4 (n = 1)).
Results
Applied DAA regimens were SOF/DAC (n = 7), SOF/LDV/RBV (n = 3), SOF/RBV (n = 3),
PTV/r/OBV/DSV (n = 1), or PTV/r/OBV/DSV/RBV (n = 1), respectively. All patients achieved
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SVR 12, in the end. In one patient, HCV relapse occurred after 24 weeks of SOF/DAC ther-
apy; subsequent treatment with 12 weeks PTV/r/OBV/DSV achieved SVR 12. One patient
underwent liver transplantation while on DAA treatment. Analysis of liver function revealed
either stable parameters or even significant improvement during DAA therapy and in follow-
up. MELD scores were found to improve in 9/13 therapies in patients on the waiting list for
liver transplantation; in only 2 patients a moderate increase of MELD scores persisted at the
end of follow-up.
Conclusion
DAA treatment was safe and highly effective in this nation-wide cohort of patients with HCV/
HIV-coinfection awaiting liver transplantation or being transplanted.
Introduction
Presumably 2.3 million Hepatitis C (HCV) positive patients worldwide are coinfected with
human immunodeficiency virus (HIV), of which about 100,000 are living in Western and Cen-
tral Europe [1]. Coinfection with HIV is known to accelerate complications of chronic HCV
infection [2], such as the development and decompensation of liver cirrhosis and emergence
of hepatocellular carcinoma (HCC). With the development of direct acting antiviral agents
(DAA), antiviral treatment has led to very high SVR (sustained virologic response) rates of 95–
100% in the past few years [3–8].
By now, substantial experience exists for DAA therapy in a variety of different patient sub-
groups. In the special subgroup of HCV/HIV-coinfected patients, DAA treatment shows safety
profiles and SVR rates that are nearly identical to those of HCV-monoinfected patients [9–14],
although drug-drug interactions (DDIs) with antiretroviral medication can be challenging in
this cohort [15, 16]. There have also been a number of trials to evaluate DAA therapy in
patients with compensated (Child-Pugh A) liver cirrhosis [17–22], demonstrating favorable
safety and efficacy profiles (SVR rates 90–95%) in HCV-monoinfected as well as in HCV/
HIV-coinfected patients [11, 12, 23]. Similar SVR rates were demonstrated for HCV-monoin-
fected patients after liver transplantation [22, 24–31]. In contrast, SVR rates are less impressive
in patients with decompensated liver cirrhosis, mainly in the range of 80–85% [3, 4, 17, 22, 26,
27, 32, 33]. Furthermore, the potential of severe deterioration of liver function under DAA
therapy in patients with advanced liver cirrhosis [17, 22, 24, 27, 32, 34] has led to the recom-
mendation of very careful usage or even refusal of DAA therapy in patients with MELD
(model for end-stage liver disease) scores exceeding 18–20 points [3, 35].
In this context, so far only few data exist concerning safety and efficacy of DAA therapy in
HCV/HIV-coinfected patients (i) exhibiting advanced stages of liver cirrhosis while waiting
for liver transplantation or (ii) undergoing DAA therapy after liver transplantation. Therefore,
we performed a retrospective multicenter analysis throughout Germany, focusing on patients
with either of these two rare conditions.
Patients and methods
For this retrospective cross-sectional multicenter analysis, 54 specialized liver centers in
Germany were contacted, including (i) all 23 German university hospitals performing liver
transplantations, (ii) 2 additional non-transplanting university hospitals, and (iii) 29 medical
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practices specialized in hepatology or infectious diseases. Responses were obtained from 22
university hospitals and 10 practices. Notably, 9 university hospitals and 1 medical practice
were able to contribute eligible patients to this study. The other institutions reported to have
no suitable patients. Data acquisition was carried out pseudonymously by use of a precast
Excel chart to ensure structured and standardized data collection. Collected data contained
basic patient characteristics, stage of liver disease, specifications of HCV and HIV disease,
course of DAA therapy, as well as laboratory results. Recorded time spans encompassed
initiation of DAA therapy (baseline) until end of follow-up (12 or 24 weeks after end of
treatment).
Complete data sets were obtained for 14 patients. One patient (Pt. 6) received a second
DAA therapy, so that a total of 15 DAA therapies were recorded as shown in Table 1. Twelve
patients were on the waiting list for liver transplantation at the initiation of DAA therapy with
Child-Pugh stage A (n = 6), B (n = 5), C (n = 1); MELD scores: range 7–21, median 13; two
patients with HCC; HCV genotypes 1a (n = 8), 1b (n = 2), 4 (n = 2); one patient underwent
liver transplantation while on DAA therapy. The decision for listing the individual patients for
liver transplantation was in the responsibility of the respective transplant center. Two patients
with HCV genotype 1a or 4, respectively, had already been transplanted at the beginning of
DAA treatment; one transplanted patient (Pt. 13) suffered from fibrosing cholestatic hepatitis
following recurrence of hepatitis C, the other (Pt. 14) from re-cirrhosis of the liver graft.
Nine patients had received previous treatment for HCV with Interferon-based therapies. All
patients suffered from HIV-1 and were under stable antiretroviral therapy: HIV stadium
A1-C3; CD4 cell count 50-1010/μl (CD4 cell count available for n = 11 patients). For more
details see Table 1.
Data analysis was performed using IBM SPSS Statistics (Version 24), GraphPad Prism (Ver-
sion 7.03), and Microsoft Excel (Version 2010). Continuous variables in dependent samples
were analyzed with Friedman’s ANOVA. P values< 0.05 were considered significant. For post
hoc analysis, Wilcoxon signed ranks test was used. Bonferroni-Holm correction was applied in
case of multiple comparisons. Retrospective simulation of potential DDIs was performed by
use of the website www.hep-druginteractions.org (University of Liverpool) [3]. HCV RNA
negativity was defined as HCV RNA PCR below the lower limit of detection in a sensitive
assay.
This study was approved by the Ethics Committee at the Medical Faculty of the Eberhard-
Karls University and at the University Hospital Tuebingen (Project number: 805/2015BO2).
The Committee waived the need for written informed consent for this retrospective analysis.
Results
DAA treatment regimens were chosen as shown in Table 1. Regimen choices were based on
the available options at the time of initiation of therapy. No patient died during treatment and
there was no case, in which DAA treatment had to be discontinued (two discontinuations of
Ribavirin). In five patients, complications were recorded as listed in Table 1. One patient
underwent liver transplantation while on DAA therapy. There were no transplant rejections
during therapy and follow-up. The antiretroviral treatment regimen was modified in one
patient (Pt. 13) prior to DAA therapy. Retrospective simulation yielded potential DDIs of
DAAs with antiretroviral medication in 11/15 therapy regimens (73.3%). Serum levels of anti-
retroviral medication were monitored in one patient. HIV RNA PCR was performed in 12/14
patients with varying frequency at non-standardized time-points. No significant HIV viremia
or viral blips were detected during DAA therapy. In the follow-up phase, only one transient
episode of low level HIV viremia was reported (Pt. 1, 89 copies/ml).
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Table 1. Individual listing of patient characteristics.
Patient Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 Pt. 6a Pt. 6ba Pt. 7 Pt. 8 Pt. 9 Pt. 10 Pt. 11 Pt. 12 Pt. 13 Pt. 14
LTx-Status pre pre pre pre pre pre pre pre pre pre pre pre pre post post
LTx LTx LTx LTx LTx LTx LTx LTx LTx LTx LTx LTx LTx LTx LTxb
General data
Age (years) 45 57 49 56 48 64 64 39 49 53 48 54 38 45 49
Sex m f f m m m m m m m m m m m m
BMI (kg/m2) 33 19 23 26 25 25 25 21 23 35 21 17 21 22 23
Child-Pugh C A B B B B B A A A A A B n/a un-
known
MELD 18 9 9 10 13 16 14 21 13 12 7 14 17 12 13
HCC no yes no no no no no no no no no no yes no no
Time since LTx n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0c 35 58
(months)
Immuno-
suppressants
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a TAC
MMF
Pred
CSA
MMF
Pred
TAC
MMF
-
HCV
Genotype 4 1a 1a 1b 4 1b 1b 1a 1a 1a 1a 1a 1a 4 1a
First diagnosed 8 31 18 32 30 18 18 35 21 21 un-
known
21 ~30 9 11
(. . . years ago)
Pretreatment with
IFN-based regimen
no no no yes no yes yes yes yes yes no yes yes yes yes
or DAA therapy no no no no no no yes no no no no no no no no
Outcome of
previous treatment
n/a n/a n/a NR n/a discontinuation relapse
after
DAA
therapy
relapse relapse NR n/a NR NR NR NR
HIV
HIV type HIV-
1
HIV-1 HIV-1 HIV-1 HIV-
1
HIV-1 HIV-1 HIV-1 HIV-1 HIV-
1
HIV-1 HIV-1 HIV-1 HIV-1 HIV-1
First diagnosed 18 31 30 32 30 17 17 35 26 27 26 27 ~30 11 15
(. . . years ago)
Stadium A2 A1 B3 C2 B3 B2 B2 C3 B3 A1 C2 C3 B3 A1 A2
HIV-Medication FTC/
TDF/
RPV
FTC/
TDF/
ATV/
RTV
3TC/
FPV/
RTV
FTC/
TDF/
LPV/
RTV
ATV FTC/TDF/FPV/
RTV
FTC/
TDF/
FPV/
RTV
DRV/
RTV
FTC/
TDF/
RAL
FTC/
TDF/
RAL
DRV/
RAL/
RTV
LPV/
RTV/
3TC/
ABC/
RAL
FTC/
TDF/
RAL
3TC/
ABC/
RAL
TDF/
3TC/
RAL
DAA therapy
HCV-Medication SOF/
DAC
SOF/
DAC
SOF/
LDV/
RBV
SOF/
DAC
SOF/
DAC
SOF/DAC PTV/r/
OBV/
DSV
PTV/r/
OBV/
DSV/
RBV
SOF/
RBV
SOF/
DAC
SOF/
LDV/
RBV
SOF/
LDV/
RBV
SOF/
RBV
SOF/
DAC
SOF/
RBV
Duration (weeks) 24 24 12 12 24 24 12 24 24 24 24 24 27 40d 24
HCV-RNA-PCR
first negative
(weeks)
4 8 2 12 8 4 4 8 12 12 24 24 6 27 8
Outcome SVR
12
SVR
12
SVR
12
SVR
12
SVR
12
relapse SVR 12 SVR 12 SVR 12 SVR
12
SVR 12 SVR 12 SVR
12
SVR
12
SVR 12
Complications yese no no no no no no no no no no yesf yesg yesh yesi
(Continued)
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Notably, 13/14 patients achieved SVR 12 following the first DAA therapy (92.9%; 11
patients on the transplant waiting list and both patients after liver transplantation). HCV RNA
negativity was reached after a median of 8 weeks during DAA therapy (range 2–27 weeks; see
Fig 1). One patient (No. 6a) suffered from a relapse following 24 weeks of therapy with Sofos-
buvir / Daclatasvir; subsequently, this patient achieved SVR 12 under a modified DAA therapy
with Paritaprevir / Ritonavir / Ombitasvir / Dasabuvir, administered over 12 weeks (see Pt.
6b).
For safety analysis, we monitored the course of liver function tests and MELD scores under
DAA therapy and during follow-up. Statistical analysis was performed on the results of the
patients on the transplant waiting list (see Table 2 and Fig 2). In all evaluable cases, significant
and persistent improvements of serum alanine transaminase (p< 0.001) and thrombocyte lev-
els (p = 0.002) could be observed. INR (international normalized ratio), bilirubin, and albumin
displayed a trend towards improvement without reaching levels of significance. Creatinine lev-
els (p = 0.002) and eGFR (estimated glomerular filtration rate; p = 0.013) showed minimal
changes of the mean, however, we could demonstrate a transient, statistically significant wors-
ening under DAA therapy. These changes remained significant even when excluding the one
patient (Pt. 7) with a markedly impaired and fluctuating renal function from analysis on a trial
basis. The two transplanted patients showed stable liver function tests under DAA therapy and
during follow-up. Especially the patient suffering from fibrosing cholestatic hepatitis (Pt. 13)
displayed a pronounced improvement in bilirubin levels, albumin, and thrombocytes.
As shown in Fig 3A, initial individual MELD scores improved in 9 patients on the trans-
plant waiting list compared to baseline: 7 patients showed sustained improvement from the
DAA treatment period until the end of follow-up, while 2 patients started to improve only
when reaching the follow-up period. One of these patients’ (Pt. 7) MELD score was mainly
driven by an impaired and fluctuating renal function. In contrast, 2 patients showed worsening
of their MELD scores persisting throughout treatment and follow-up. MELD scores in another
Table 1. (Continued)
Patient Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 Pt. 6a Pt. 6ba Pt. 7 Pt. 8 Pt. 9 Pt. 10 Pt. 11 Pt. 12 Pt. 13 Pt. 14
Transplant
rejection during
DAA therapy
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a no no no
Pt. 1–14 = Patients 1–14; LTx = liver transplantation; pre LTx = patient on liver transplant waiting list at initiation of DAA therapy; post LTx = DAA therapy was
initiated after liver transplantation; m = male; f = female; BMI = body mass index; n/a = not applicable; MELD = model for end-stage liver disease;
HCC = hepatocellular carcinoma; TAC = Tacrolimus; MMF = Mycophenolate mofetil; Pred = Prednisolone; CSA = Ciclosporin; IFN = Interferon; NR = nonresponse;
FTC = Emtricitabine; TDF = Tenofovir; RPV = Rilpivirine; ATV = Atazanavir; RTV = Ritonavir; 3TC = Lamivudine; FPV = Fosamprenavir; LPV = Lopinavir;
DRV = Darunavir; RAL = Raltegravir; ABC = Abacavir; SOF = Sofosbuvir; DAC = Daclatasvir; LDV = Ledipasvir; RBV = Ribavirin; PTV = Paritaprevir; r = Ritonavir;
OBV = Ombitasvir; DSV = Dasabuvir; PCR = polymerase chain reaction; SVR 12 = sustained virologic response 12 weeks after end of treatment.
a relapse after SOF/DAC (24 weeks), SVR 12 achieved after second therapy with PTV/r/OBV/DSV (12 weeks);
b re-cirrhosis in transplanted liver;
c LTx three weeks after initiation of DAA therapy, initial immunosuppressive therapy with TAC/MMF/Pred, TAC switched to Sirolimus during DAA therapy;
d 40 weeks of therapy, addition of RBV after three months (discontinuation after 14 days due to worsening of renal function), and SMV after four months, respectively,
due to a delayed drop in HCV RNA levels;
e biliary stent occlusion with cholangitis;
f hemolytic anemia, resulting in discontinuation of RBV;
g HCC recurrence after LTx;
h fibrosing cholestatic hepatitis, renal insufficiency, incisional hernia;
i abdominal pain.
https://doi.org/10.1371/journal.pone.0197544.t001
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2 patients returned to baseline at the follow-up period after initial worsening under DAA ther-
apy. Overall, changes in MELD scores did not reach a level of significance (see Table 2 and Fig
3B).
Discussion
In this retrospective German multicenter study, data on safety and efficacy of DAA therapy in
patients with HCV/HIV-coinfection on the liver transplant waiting list or after liver transplan-
tation, respectively, were analyzed. SVR rates in this rare patient subgroup were encouragingly
high: Although a substantial number of patients with decompensated liver cirrhosis (50%
Child-Pugh B/C) were included, all chronic HCV infections were cured, including the one
patient who achieved SVR only after a second, modified DAA treatment. Our results seem to
slightly exceed SVR rates in the one and only case series including HCV/HIV-coinfected
patients on the liver transplant waiting list, which has yet been published [37]. This study
reported an overall SVR rate of 85.4% (79.2% pre liver transplantation) while not discussing
the possibility for re-treatment in case of failure. Our data are also slightly exceeding results for
DAA treatment in advanced liver disease for HCV-monoinfected patients in prospective trials
such as SOLAR-1 [26], SOLAR-2 [27], ASTRAL-4 [32], CUP [17], ALLY-1 [22], as well as in
larger real-world cohort analyses [4, 17]. This may be due to the small sample size and highly
selected patients in our study. Furthermore, DAA treatment was solely performed in highly
specialized and experienced liver centers, which might have contributed to these optimal
outcomes.
Fig 1. Course of HCV RNA under DAA therapy. Pt. 1–14: individual patients. T 0 = initiation of DAA therapy; T 4/12/24 = 4/12/24 weeks after
initiation of DAA treatment (T24 only if treatment course was long enough). Undetectable HCV RNA was set to zero in the otherwise logarithmized
data.
https://doi.org/10.1371/journal.pone.0197544.g001
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Table 2. Changes in laboratory results under DAA therapy and during follow-up in patients on the liver transplant waiting list.
Parameter N Baseline EOT EO FU p-value
ALT Mean ± SEM 13 70 ± 14.7 24 ± 2.9 27 ± 2.6 <0.001
(U/l) Range 21–212 8–43 17–52
Thrombocytes Mean ± SEM 12 60 ± 10.0 84 ± 14.0 92 ± 15.5 0.002
(1,000/μl) Range 25–135 29–187 27–175
MELD Mean ± SEM 11 14 ± 1.2 13 ± 1.7 11 ± 1.4 0.307
Range 7–21 6–27 5–22
Bilirubin (total) Mean ± SEM 13 2.6 ± 0.4 2.5 ± 0.5 1.9 ± 0.3 0.101
(mg/dl) Range 0.5–6.0 0.6–6.8 0.4–4.2
INR Mean ± SEM 13 1.2 ± 0.05 1.2 ± 0.02 1.2 ± 0.02 0.832
Range 1.1–1.6 1.0–1.3 1.1–1.3
Albumin Mean ± SEM 9 3.4 ± 0.2 3.9 ± 0.2 4.0 ± 0.2 0.169
(g/dl) Range 2.6–4.2 3.2–4.8 2.7–5.1
Creatinine Mean ± SEM 13 1.3 ± 0.3 1.5 ± 0.5 1.2 ± 0.3 0.002
(mg/dl) Range 0.6–4.8 0.6–7.1 0.6–4.3
eGFR Mean ± SEM 13 84 ± 27.6 79 ± 27.9 86 ± 25.7 0.013
(ml/min/1,73m2) Range 14–119 9–116 16–119
Analysis was only possible for data sets, in which values for all three time points (baseline, end of treatment (EOT), end of follow-up (EO FU)) were given. Significant p-
values (Friedman’s ANOVA) are printed in bold. Mean, standard error of the mean (SEM), and range are indicated for the three time points. N = number of data sets of
DAA therapies which could be analyzed per parameter; ALT = alanine transaminase; MELD = model for end-stage liver disease; INR = international normalized ratio;
eGFR = estimated glomerular filtration rate. Calculation of eGFR by use of the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation [36].
https://doi.org/10.1371/journal.pone.0197544.t002
Fig 2. Changes of (A) alanine transaminase (ALT), (B) bilirubin, (C) albumin, (D) thrombocytes, (E) INR (international normalized ratio), and
(F) creatinine in patients on the liver transplant waiting list. Box plots: median and interquartile ranges; whiskers: minimum to maximum. P-values
from post hoc analysis (Wilcoxon signed ranks test, Bonferroni-Holm correction); ns = not significant, EOT = end of treatment, EO FU = end of
follow-up.
https://doi.org/10.1371/journal.pone.0197544.g002
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In addition to the remarkable SVR rates, our data demonstrate a tolerable safety profile of
DAA therapy in this special cohort. Most recorded complications show no clear association
to antiviral therapy. Moreover, we could demonstrate an overall stability of liver function
during DAA therapy and in follow-up. Statistical analysis revealed transient significant wors-
ening of creatinine levels and eGFR under DAA therapy. However, changes of the mean
were very small and most patients had normal or nearly normal renal function throughout
observation. This caused a pronounced floor effect impairing the impact of this result. Fur-
thermore, in all patients receiving antiretroviral regimens containing Tenofovir, eGFR did
not fall below the threshold associated with a risk of accumulation. MELD score changes
with approximately half of the patients showing improvement are consistent with data for
HCV-monoinfected patients with decompensated liver cirrhosis [32]. Furthermore, the sig-
nificant and sustained improvement of thrombocyte levels could be taken as an indicator for
reduction in portal hypertension. Our findings are in line with data on long-term outcome
in HCV-monoinfected patients on the liver transplant waiting list, in which successful DAA
therapy can lead to significant improvement and stabilization of liver function, even enabling
patients to be removed from the transplant waiting list [33, 35]. Interestingly, there were no
reports on any clinically relevant adverse drug effects, although retrospective screening for
DDIs of DAAs with the antiretroviral medication yielded potential interactions in 73% of the
patients.
There are three reports in the literature [38–40] dealing with the subject of DAA therapy in
altogether 15 HCV/HIV-coinfected patients after liver transplantation. High SVR rates, but
also several complications, especially one rejection and one case of death [38], were reported.
Our two liver transplant patients undergoing DAA therapy both achieved SVR 12 and did not
suffer from any severe complication.
Considering the high response rate of the specialized centers, the relatively small number of
patients that were detected in our study probably comes close to the actual size of this very rare
subgroup of patients in Germany. Our data correspond to different cohort studies stating a
prevalence of 2.6–3.0% [41, 42] for HCV/HIV-coinfected patients on the liver transplant wait-
ing list, and a prevalence of 0.2–0.3% [43, 44] for HCV/HIV-coinfected patients after liver
transplantation.
Fig 3. (A) Changes of MELD scores in patients on the liver transplant waiting list. Changes did not reach significance levels; ns = not significant,
EOT = end of treatment, EO FU = end of follow-up. (B) Changes of individual MELD scores in patients on the liver transplant waiting list. Pt. 1–12:
individual patients. EOT = end of treatment, EO FU = end of follow-up.
https://doi.org/10.1371/journal.pone.0197544.g003
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Many questions remain to be answered for this special patient collective: Besides providing
further proof for safety and efficacy of DAA treatment, future studies should focus on the
choice of DAA regimens, the clinical relevance of potential DDIs, as well as the patients’ long-
term outcome. Given the low prevalence of HCV/HIV-coinfected patients on the liver trans-
plant waiting list and after liver transplantation, respectively, international studies are required
to recruit a sufficient number of patients.
In summary, our data strongly suggest that DAA treatment can be performed with excellent
efficacy and tolerable safety in patients with HCV/HIV-coinfection and advanced liver cirrho-
sis on the liver transplant waiting list as well as in HCV/HIV-coinfected patients after liver
transplantation. However, considering this challenging patient population, DAA therapy
should preferably be performed in specialized liver centers comprising particular knowledge
in managing patients with HIV-infection.
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